Source: Coveo
  • Coveo Solutions (CVO) has closed its initial public offering for gross proceeds of C$215 million
  • The company issued 14,340,000 subordinate voting shares at a price of C$15.00 per share
  • Coveo has also closed a direct private placement of 129,996 subordinate voting shares
  • Coveo’s SaaS-native, multi-tenant platform injects search, recommendations, and personalization solutions into digital experiences
  • Coveo Solutions Inc. subordinate voting shares (TSX:CVO) are up 0.664 per cent on the day, trading at $15.16 per share at 10:20 am EST

Coveo Solutions (CVO) has closed its initial public offering for gross proceeds of C$215 million.

The company issued 14,340,000 subordinate voting shares at a price of C$15.00 per share.

The subordinate voting shares began trading on the TSX on November 18 under the symbol CVO.

The offering was made through a syndicate of underwriters led by BMO Capital Markets, BofA Securities, RBC Capital Markets and UBS Investment Bank.

The company has granted to the underwriters an over-allotment option to purchase up to an additional 2,151,000 subordinate voting shares. If the option is exercised in full, the gross proceeds of the offering will be C$247,365,000. 

Coveo has also closed a direct private placement of 129,996 subordinate voting shares to certain customers, suppliers and other business partners residing outside Canada on the same terms as the offering.

Coveo is an AI-powered relevance platform. Coveo’s SaaS-native, multi-tenant platform injects search, recommendations, and personalization solutions into digital experiences.

Coveo Solutions Inc. subordinate voting shares (TSX:CVO) are up 0.664 per cent on the day, trading at $15.16 per share at 10:20 am EST.

More From The Market Online

Westinghouse Electric files for US IPO

Westinghouse Electric Company, jointly owned by Cameco and Brookfield Renewable Partners, confidentially filed for a US IPO.

Buzz on the Bullboards: Contracts, cashflows, and delistings

Uncertainty around Iran has weighed on sentiment, reminding investors that even strong stories can be overshadowed by geopolitical risk.

EU authorizes new COVID vaccine from Pfizer and BioNTech

The EU grants marketing authorization to Pfizer and BioNTech's COVID-19 vaccine targeting the new XFG variant.